title: The effect of different physiotherapy interventions in post-BTX-A treatment of children with cerebral palsy.
abstract: OBJECTIVE
  To distinguish the effects of different physiotherapeutic programs in a post BTX-A regime for children with Cerebral Palsy (CP).
  
  
  METHODS
  Retrospective, controlled intervention study.
  
  
  METHODS
  A group of 38 children (X¯ = 7y7m, GMFCS I-III, 27 bilateral, 11 unilateral CP) receiving an individually defined Neurodevelopment Treatment (NDT) program, was matched and compared to a group of children with the same age, GMFCS and diagnosis, receiving more conventional physiotherapy treatment. All patients received selective tone-reduction by means of multilevel BTX-A injections and adequate follow-up treatment, including physiotherapy.
  
  
  METHODS
  Three-dimensional gait analyses and clinical examination was performed pre and two months post-injection. Treatment success was defined using the Goal Attainment Scale (GAS).
  
  
  RESULTS
  Both groups' mean converted GAS scores were above 50. The average converted GAS score was higher in the group of children receiving NDT than in the group receiving conventional physiotherapy (p < 0.05). In the NDT group, overall treatment success was achieved in 76% of the goals, compared to 67% of the goals defined for the conventional physiotherapy group. Especially for the goals based on gait analyses (p < 0.05) and in the group of children with bilateral CP (p < 0.05), treatment success was higher in the NDT group.
  
  
  CONCLUSIONS
  In a post-BTX-A regime, the short-term effects of an NDT approach are more pronouncedthan these from a conventional physiotherapy approach.
authors.affiliation: Clinical Motion Analysis Laboratory, University Hospital Pellenberg, Weligerveld 1, 3212 Pellenberg, Belgium. Kaat.Desloovere@uz.kuleuven.ac.be
authors.forename: K
authors.initials: K
authors.lastname: Desloovere
authors.forename: J
authors.initials: J
authors.lastname: De Cat
authors.forename: G
authors.initials: G
authors.lastname: Molenaers
authors.forename: I
authors.initials: I
authors.lastname: Franki
authors.forename: E
authors.initials: E
authors.lastname: Himpens
authors.forename: H
authors.initials: H
authors.lastname: Van Waelvelde
authors.forename: K
authors.initials: K
authors.lastname: Fagard
authors.forename: C
authors.initials: C
authors.lastname: Van den Broeck
mesh_terms: D000293:Adolescent; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage* / Q000009:adverse effects; D002547:Cerebral Palsy / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D009128:Muscle Spasticity / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*; D009465:Neuromuscular Agents / Q000008:administration & dosage* / Q000009:adverse effects; D026741:Physical Therapy Modalities; D012189:Retrospective Studies; D016037:Single-Blind Method; D016896:Treatment Outcome
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A